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Abstract
Background  and  objective: Studies  have  shown  that  the  rate  of  propofol  infusion  may  inﬂuence
the predicted  propofol  concentration  at  the  effect  site  (Es).  The  aim  of  this  study  was  to
evaluate the  Es  predicted  by  the  Marsh  pharmacokinetic  model  (ke0  0.26  min−1)  in  loss  of
consciousness  during  fast  or  slow  induction.
Method:  The  study  included  28  patients  randomly  divided  into  two  equal  groups.  In  slow  induc-
tion group  (S),  target-controlled  infusion  (TCI)  of  propofol  with  plasma,  Marsh  pharmacokinetic
model (ke0  0.26  min−1)  with  target  concentration  (Tc)  at  2.0-g  mL−1 were  administered.  WhenIntravenous the predicted  propofol  concentration  at  the  effect  site  (Es)  reached  half  of  Es  value,  Es  was
increased to  previous  Es  +  1  g  mL−1,  successively,  until  loss  of  consciousness.  In  rapid  induction
duced  with  TCI  of  propofol  with  plasma  (6.0  g  mL−1)  at  effect  site,group (R),  patients  were  in
and waited  until  loss  of  consciousness.
 Study developed at CET/SBA of Instituto Penido Burnier e Centro Médico de Campinas.
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Results:  In  rapid  induction  group,  Tc  for  loss  of  consciousness  was  signiﬁcantly  lower  compared
to slow  induction  group  (1.67  ±  0.76  and  2.50  ±  0.56  g  mL−1,  respectively,  p  =  0.004).
Conclusion:  The  predicted  propofol  concentration  at  the  effect  site  for  loss  of  consciousness  is
different for  rapid  induction  and  slow  induction,  even  with  the  same  pharmacokinetic  model
of propofol  and  the  same  balance  constant  between  plasma  and  effect  site.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
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Estudo  comparativo  entre  induc¸ão rápida  e  lenta  de  propofol  em  infusão
alvo-controlada:  concentrac¸ão de  propofol  prevista  no  local  de  ac¸ão.  Ensaio  clínico
aleatório
Resumo
Justiﬁcativa  e  objetivo: Estudos  mostraram  que  a  taxa  de  infusão  de  propofol  pode  inﬂuenciar
na concentrac¸ão  prevista  de  propofol  no  local  de  ac¸ão  (Ce).  O  objetivo  deste  estudo  foi  avaliar
a Ce  prevista  pelo  modelo  farmacocinético  de  Marsh  (ke0  0,26  min−1)  na  perda  da  consciência
durante  induc¸ão  rápida  ou  lenta.
Método:  Participaram  deste  estudo  28  pacientes,  divididos  aleatoriamente  em  dois  grupos
iguais. No  grupo  induc¸ão  lenta  (L),  foram  induzidos  com  propofol  em  infusão  alvo-controlada
(IAC) plasmática,  modelo  farmacocinético  de  Marsh  (ke0  0,26  min−1),  com  concentrac¸ão  alvo
(Ca) em  2,0  g.ml−1.  Quando  a  concentrac¸ão  de  propofol  prevista  no  local  de  ac¸ão  (Ce)  atingia
metade do  valor  da  Ca,  aumentava-se  a  Ca  para  Ca  anterior  +  1  g.ml−1.  Assim  sucessivamente
até o  momento  da  perda  da  consciência  do  paciente.  No  grupo  induc¸ão  rápida  (R),  os  pacientes
foram induzidos  com  propofol  em  IAC  plasmática  com  Ca  em  6,0  g.ml−1 e  aguardava-se  a  perda
da consciência  do  paciente.
Resultados:  No  grupo  induc¸ão  rápida,  a  Ce  na  perda  da  consciência  foi  signiﬁcativamente  mais
baixa em  relac¸ão  ao  grupo  de  induc¸ão  lenta  (1,67  ±  0,76  e  2,50  ±  0,56  g.ml−1,  respectiva-
mente, p  =  0,004).
Conclusão:  A  concentrac¸ão  prevista  de  propofol  no  local  de  ac¸ão  durante  a  perda  da  con-
sciência  é  diferente  numa  induc¸ão  rápida  e  numa  induc¸ão  lenta,  até  com  o  mesmo  modelo
farmacocinético  de  propofol  e  a  mesma  constante  de  equilíbrio  entre  o  plasma  e  o  local  de
ac¸ão.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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intravenous  anesthesia  with  propofol  and  remifentanil,  werentroduction
ecently  several  studies  have  shown  a  good  correlation
etween  the  predicted  propofol  concentration  at  the
ffect  site  (Es)  by  Marsh  pharmacokinetic  model  (ke0
.26  min−1)  and  sedation  degree,  bispectral  index  (BIS)  val-
es,  entropy,  evoked  potential  index,  and  loss  and  recovery
f  consciousness.1--5
Because  of  this  good  correlation  with  pharmacodynam-
cs,  some  authors  suggested  that  the  target  concentration
f  propofol  should  be  titrated  during  maintenance  of  anes-
hesia  based  on  Es  reached  in  loss  of  consciousness.3,4,6
However,  other  studies  show  that  the  rate  of  infusion
f  propofol  may  inﬂuence  the  balance  between  the  plasma
oncentration  and  the  concentration  at  the  effect  site;  that
s,  in  the  ﬁrst-order  mathematical  constant  called  Ke0.7,8
The  main  objective  of  this  study  was  to  evaluate
he  Es  predicted  by  the  Marsh  pharmacokinetic  model
ke0  0.26  min−1)  on  loss  of  consciousness  during  rapid
r  slow  induction  of  patients  undergoing  laparoscopic
e
Tholecystectomy  under  total  intravenous  anesthesia  with
ropofol  and  remifentanil.  Es  was  also  evaluated  during
nesthesia  maintenance  and  recovery.
The  hypothesis  to  be  tested  is  that,  even  using  the  same
harmacokinetic  model  and  the  same  equilibrium  constant
etween  plasma  and  effect  site,  the  effect  site  in  rapid
nduction  is  different  from  that  in  slow  induction  during  loss
f  consciousnesses.
ethod
fter  approval  by  the  Research  Ethics  Committee  and  receiv-
ng  the  written  informed  consent,  28  patients,  aged  between
8  and  65  years,  of  both  sexes,  ASA  physical  status  1  and  2,
nd  undergoing  laparoscopic  cholecystectomy  under  totalnrolled  in  this  randomized  clinical  trial.
The  sample  size  was  based  on  a  previous  pilot  study.
aking  into  account  that  the  difference  of  proportionality
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Table  1  Age,  weight,  height  and  sex  of  patients  per  group.
Group  Age  (years)  Weight  (kg)  Height  (cm)  Sex
(m/f)
S  43.1  ±  11.8  70.7  ±  16.9  167.1  ±  9.3  5/9
Table  2  Induction,  duration  of  surgery,  awakening  times,
and propofol  and  remifentanil  consumption.
L  R
Induction  time  (min)  4.54  ±  0.67  1.46  ±  1.02a
Duration  of  surgery  (min) 47.6  ±  13.2 50.6  ±  13.1
Awakening  time  (min)  7.21  ±  3.81  7.07  ±  5.18
Propofol  (mg  kg−1 h−1)  8.27  ±  2.15  8.40  ±  1.68
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Studies  have  shown  that  the  pharmacokinetic  models
of  propofol  used  in  target-controlled  infusion  systems  are
poorly  accurate  for  early  prediction  of  propofol  actual  blood
concentration  after  bolus  or  rapid  infusion,  when  maximum
LOC S LOV R IO S IO R ROC S ROC R
1.0
1.5
2.0
2.5
3.0
3.5
4.0
D
at
a
a
−1R 46.8  ±  12.0  76.5  ±  8.64  166.2  ±  8.8  6/8
S, slow induction group; R, rapid induction group; p > 0.05.
between  the  propofol  concentrations  provided  on  the  effect
site  during  loss  of  consciousness  with  rapid  and  slow  infusion
was  67%,  the  power  analysis  with  alpha  of  1%  and  beta  of
5%  showed  that  11  patients  would  be  required  per  group.
Three  more  patients  per  group  were  added  to  compensate
for  possible  losses  during  the  clinical  trial.
No  patient  received  premedication  and  all  were  moni-
tored  with  electrocardiogram  (DII  and  V1),  pulse  oximetry,
non-invasive  mean  arterial  blood  pressure  (MAP),  bispectral
index  (BIS),  and  end-tidal  CO2 after  tracheal  intubation.
Patients  were  randomly  allocated  into  two  equal  groups
through  a  deﬁned  sequence  by  computer.  The  slow  induction
group  (Group  S)  received  propofol  by  plasma  target-
controlled  infusion  (TCI),  Marsh  pharmacokinetic  model  (ke0
0.26  min−1),  with  target  concentration  (Tc)  of  2.0  g  mL−1.
When  the  predicted  propofol  concentration  at  the  effect
site  (Es)  reached  half  the  value  of  Tc,  Tc  was  increased  to
previous  Tc  +  1  g  mL−1,  and  so  on  until  the  patient’s  loss  of
consciousness  (loss  of  verbal  response  and  eye-blink  reﬂex).
The  rapid  induction  group  (Group  R)  received  plasma  propo-
fol  via  TCI  with  6  g  mL−1 Tc  and  waited  until  patient’s  loss
of  consciousness.
In  both  groups,  after  loss  of  consciousness,  TCI
remifentanil  was  initiated  to  an  effect  site  of  5  g  mL−1
(Minto’s  pharmacokinetic  model),  rocuronium  0.6  mg  kg−1
was  administered,  and  after  two  minutes  tracheal  intubation
was  performed.
During  the  intraoperative  period,  Tc  of  propofol  was
adjusted  to  maintain  BIS  between  35  and  50,  while  Tc  of
remifentanil  was  adjusted  to  maintain  MAP  between  ±20%
of  the  initial  MAP.
After  surgery,  both  infusions  were  turned  off.
Es  of  propofol  was  recorded  at  the  time  of  loss  and
recovery  of  consciousness  (BIS  =  70)  and  every  minute  of  the
intraoperative  period.
All  patients  received  dipyrone  30  mg  kg−1 and  ketopro-
fen  1.5  mg  kg−1 for  postoperative  analgesia  and  methadone
0.1  mg  kg−1 as  rescue  analgesic  in  the  Post-Anesthesia  Care
Unit.
For  infusion  management  and  data  collection,  the
Anestfusor® software,  coupled  to  two  Pilot  2  syringe  pumps
(Fresenius-Kabi)  and  BIS,  was  used.
For  statistical  analysis  of  parametric  data,  Student’s  t-
test  was  used  and  the  difference  was  considered  signiﬁcant
when  p  values  were  <0.05.
ResultsThere  was  no  signiﬁcant  difference  between  demographic
variables  of  the  two  groups  (p  >  0.05)  (Table  1).
Induction  time  in  Group  S  was  higher  compared  to  Group
R,  4.54  and  1.46  min,  respectively  (p  <  0.001).  There  was  no
F
S
c
nRemifentanil  (g  kg−1 min−1)  0.16  ±  0.02  0.13  ±  0.03
a p < 0.001.
igniﬁcant  difference  in  surgery  and  awakening  times  and
onsumption  of  propofol  and  remifentanil  between  the  two
roups  (p  >  0.05)  (Table  2).
The  predicted  propofol  effect-site  concentration  (Es)  in
oss  of  consciousness  was  higher  in  Group  S  compared  to
roup  R,  2.50  and  1.67  g  mL−1 respectively  (p  =  0.004).
s  was  signiﬁcantly  different  at  loss  and  recovery  of  con-
ciousness  in  Group  S,  2.5  and  1.60  g  mL−1, respectively
p  <  0.001).  In  Group  R,  Es  was  lower  at  loss  of  conscious-
ess  compared  to  intraoperative  Es,  1.67  and  2.52  g  mL−1,
espectively  (p  =  0.002).  There  was  no  signiﬁcant  differ-
nce  between  groups  regarding  Es  values’  intraoperative
nd  at  recovery  of  consciousness  (p  >  0.05).  There  was  also
o  signiﬁcant  difference  in  Es  during  loss  and  recovery  of
onsciousness  in  Group  R  (p  >  0.05)  (Fig.  1).
iscussion
he  main  difference  found  in  this  study  was  the  Es  predicted
y  the  Marsh  pharmacokinetic  model  (ke0  0.26  min−1)  during
oss  of  consciousness  between  rapid  and  slow  induction.
Although  the  same  pharmacokinetic  model  and  the  same
quilibrium  constant  plasma/effect-site  (Ke0)  have  been
sed,  Es  at  loss  of  consciousness  was  signiﬁcantly  lower
n  Group  R  compared  to  Group  S,  1.67  and  2.50  g  mL−1,
espectively.  This  difference  was  also  found  by  other
uthors.8igure  1  Effect-site  concentration  of  propofol  (mcg  mL ).
, slow  induction  group;  R,  rapid  induction  group;  LOC,  loss  of
onsciousness;  IO,  intraoperatively;  ROC,  recovery  of  conscious-
ess; a vs  •  p  =  0.004; a vs    p  <  0.001;  •  vs  ©  p  =  0.002.
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ffect  is  observed.7,9--11 These  conventional  nipple  multi-
ompartmental  pharmacokinetic  models  assume  that  drug
ixing  in  central  compartment  occurs  immediately  and  the
ixture  immediately  appears  in  the  arterial  circulation.  In
act,  there  is  a  delay  between  the  drug  administration  and
ts  appearance  in  arterial  blood.  This  has  been  reported  in
everal  studies.7,12,13
Among  other  factors,  this  delay  depends  on  the  pul-
onary  extraction  of  propofol  during  the  ﬁrst  pass.14,15 In
arsh  pharmacokinetic  model,  this  initial  error  is  evident
uring  the  ﬁrst  ﬁve  minutes,  which  makes  the  model  not  so
recise  for  these  ﬁrst  minutes.7
By  assuming  an  instantaneous  mixture  after  a  bolus  injec-
ion,  the  traditional  pharmacokinetic  models  overestimate
he  central  volume.  Because  the  bolus  dose  depends  on  the
ize  of  the  central  compartment,  its  overestimation  may
esult  in  a  large  bolus,  which  may  exceed  the  target  concen-
ration  whenever  the  target  is  increased.14,15
Because  of  this  poor  predictability  of  pharmacokinetic
odel  in  the  ﬁrst  minutes  after  a  bolus  injection,  some
uthors  have  shown  that  the  rate  of  propofol  infusion  can
nﬂuence  the  equilibrium  constant  between  plasma  and
ffect  site.7 Apparently,  the  plasma/effect-site  equilibrium
onstant  is  faster  for  bolus  administration  than  for  slower
nfusions.  This  may  answer  why  different  ke0  are  found  in
he  literature,  even  when  using  the  same  pharmacokinetic
odel.7
Maybe  there  are  physiological  reasons  for  these  different
alues  of  ke0  obtained  through  bolus  and  slower  infusions.
ne  study  showed  that  propofol  reduces  cerebral  blood  ﬂow
n  a  dose-dependent  manner.16 So,  when  using  a  bolus  injec-
ion  to  extract  ke0,  the  achieved  high  concentrations  of
ropofol  may  reduce  cerebral  blood  ﬂow.  On  the  other  hand,
hen  slower  infusions  are  used,  this  propofol  effect  on  cere-
ral  blood  ﬂow  should  be  reduced.
With  the  use  of  a  conventional  continuous  infusion
cheme,  the  values  for  propofol  t½ ke0  in  literature  vary
etween  2.3  and  3.5  min.17--19 The  Marsh  pharmacokinetic
odel,  which  is  present  in  the  ﬁrst  target-controlled  infu-
ion  system  commercially  available  (Diprifusor),  was  based
n  data  from  a  slow  infusion  and  is  associated  with  a t½ ke0
f  2.65  min.17
As  an  option  to  reduce  this  initial  error  of  the  propo-
ol  pharmacokinetic  models,  some  authors  have  proposed
o  incorporate  into  the  Schnider  model  different  ke0  val-
es  for  different  infusion  rates.7 If  the  maximum  infusion
ate  remains  between  300  and  900  mL  h−1,  t½ ke0  should
e  about  2.2  min  (ke0  =  0.32  min−1).  However,  if  the  infusion
s  similar  to  a  bolus  injection,  a  shorter  t½ ke0  of  1.2  min
hould  be  used.
For  other  pharmacokinetic  models  of  propofol  as  the
arsh,  for  example,  if  the  pump  is  capable  of  delivering  a
olus  induction  in  a  minute  or  less,  the  time  must  be  imple-
ented  to  maximum  effect  of  1.5  min.7 With  these  options,
his  model  predicted  effect  concentration  is  more  accurate
ver  time.
Some  authors  have  assessed  more  appropriate  phar-
acokinetic  models  for  this  initial  kinetic  phase  and  the
orrelation  with  possible  covariates  such  as  age,  weight,
nd  infusion  rate.20 In  these  more  sophisticated  models,
t  was  demonstrated  that  the  use  of  a  single  ke0  value  is
ppropriate  and  can  be  applied  to  the  target  controlled
T
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nfusion  systems,  which  use  syringe  pumps  with  infusion
ate  between  10  and  160  mg  kg−1 h−1.  Therefore,  for  these
tudies,  pharmacodynamics  is  not  inﬂuenced  by  the  rate  of
ropofol  infusion.20,21
The  mean  values  of  Es  in  rapid  and  slow  induction  groups
ere  similar  during  the  intraoperative  and  recovery  of
onsciousness  times,  2.52  ±  0.43  and  2.52  ±  0.76  g  mL−1,
espectively,  and  1.63  ±  0.42  and  1.60  ±  0.58  g mL−1,
espectively.
As  shown  in  some  studies,  Es  of  propofol  for  loss
nd  recovery  of  consciousness  are  similar  when  using  the
arsh  pharmacokinetic  model  (ke0  0.26  min−1).3,4 There-
ore,  some  authors  suggested  that  the  target  concentration
f  propofol  should  be  titrated  during  maintenance  of  anes-
hesia  based  on  Es  during  loss  of  consciousness.3,4,6 The  main
bjective  would  be  to  reduce  the  possibility  of  patient  awak-
ning  during  surgery.  It  is  worth  noting  that  this  is  only  valid
hen  analgesia  is  complete  throughout  the  procedure.
To  date,  the  literature  on  the  subject  does  not  allow  say-
ng  that  the  actual  propofol  concentration  at  the  effect  site
s  similar  at  loss  and  recovery  of  consciousness  or  that  it  is
eally  different.
Recently,  a  study  showed  that  regardless  of  the  pharma-
okinetic  model  of  propofol  used  (Schnider:  ke0  0.45  min−1
nd  time  to  peak  effect  1.7  min;  Marsh:  ke0  1.21  min−1
nd  time  to  peak  effect  1.7  min;  or  Marsh:  ke0  0.26  min−1
nd  time  to  peak  effect  of  4.5  min),  the  predicted  value
f  propofol  at  the  effect  site  during  loss  of  consciousness
fter  a  bolus  injection  should  not  be  used  as  reference  value
or  titration  of  hypnosis  during  maintenance  of  anesthesia,
s  the  effect  concentration  of  propofol  predicted  by  these
odels  during  loss  of  consciousness  is  very  different  (4.40,
.55  and  1.28  g  mL−1,  respectively).8
In  this  study,  the  rapid  and  slow  induction  groups  showed
imilar  Es  at  recovery  of  consciousness.  However,  Es  at  loss
nd  recovery  of  consciousness  was  similar  only  in  the  rapid
nduction  group  (Fig.  1).
Based  on  the  presented  results,  we  can  conclude  that  in
ases  of  rapid  induction  with  Marsh  model  (ke0  0.26  min−1),
s  at  loss  and  recovery  of  consciousness  is  similar  (1.63  and
.60  g  mL−1,  respectively).  However,  Es  during  the  intraop-
rative  period  should  be  about  50%  higher.
In  cases  of  slow  induction,  the  target  maintenance  dose
ay  be  similar  to  the  Es  during  loss  of  consciousness.  This
esult  was  expected,  as  the  ke0  used  in  this  study  was
erived  from  slow  infusion  data.17 Consequently,  the  pre-
icted  effect-site  concentration  of  propofol  over  time  is
ore  precise.
Although  the  goal  was  to  evaluate  the  predicted  effect-
ite  concentration  of  propofol,  the  main  limitation  of  this
tudy  was  not  measuring  the  plasma  concentration  of  propo-
ol  at  different  times.
Another  aspect  to  be  considered  is  that  the  use  of
atients  of  both  sexes  may  have  increased  the  study  bias,  as
ex  is  an  important  variable  in  propofol  pharmacokinetics.22
owever,  there  was  no  signiﬁcant  difference  between
roups  in  the  number  of  patients  of  both  genders.he  predicted  effect-site  concentration  of  propofol  at  loss  of
onsciousness  is  different  in  a rapid  induction  and  in  a  slow
pofo
1
1
1
1
1
1
1
1
1
1
2
2Comparative  study  between  rapid  and  slow  induction  of  pro
induction,  even  with  the  same  pharmacokinetic  model  of
propofol  and  the  same  equilibrium  constant  between  plasma
and  effect  site.  Recognizing  this  difference  is  crucial  to  per-
form  a  total  intravenous  anesthesia  with  target-controlled
infusion  of  propofol  safely  for  the  patient.
Conﬂicts of interest
The  authors  declare  no  conﬂicts  of  interest.
References
1. Gajraj RJ, Doi M, Mantzaridis H. Comparison of bispectral
EEG analysis and auditory evoked potentials for monitoring
depth of anaesthesia during propofol anaesthesia. Br J Anaesth.
1999;82:672--8.
2. Barakat AR, Sutcliffe N, Schwab M. Effect site concen-
tration during propofol TCI sedation: a comparison of
sedation score with two pharmacokinetic models. Anaesthesia.
2007;62:661--6.
3. Iwakiri H, Nishihara N, Nagata O. Individual effect-site concen-
trations of propofol are similar at loss of consciousness and at
awakening. Anesth Analg. 2005;100:107--10.
4. Simoni RF, Esteves LO, Miziara LEPG, et al. Avaliac¸ão clínica de
duas ke0 no mesmo modelo farmacocinético de propofol: estudo
da perda e recuperac¸ão da consciência. Rev Bras Anestesiol.
2011;61:397--408.
5. Iannuzzi M, Iannuzzi E, Rossi F, et al. Relationship between
bispectral index, electroencephalograﬁc state entropy, and
effect-site EC50 for propofol at different clinical endpoints. Br
J Anaesth. 2005;94:613--6.
6. Lysakowsky C, Elia N, Czarnetzki C, et al. Bispectral and spec-
tral entropy indices at propofol-induced loss of consciousness
in young and elderly patients. Br J Anaesth. 2009;103:387--93.
7. Struys MMRF, Coppens MJ, Neve ND, et al. Inﬂuence of admin-
istration rate on propofol plasma-effect site equilibration.
Anesthesiology. 2007;107:386--96.
8. Sepulveda PO, Cortinez LI, Recart A, et al. Predictive ability of
propofol effect-site concentrations during fast and slow infusion
rates. Acta Anaesthesiol Scand. 2010;54:447--52.
9. Schnider TW, Minto CF, Shafer SL, et al. The inﬂuence of age in
propofol pharmacodynamics. Anesthesiology. 1999;90:1502--16.
2l  103
0. Kasama T, Morita K, Ikeda T, et al. Comparison of predicted
induction dose with predetermined physiologic characteristics
of patients and with pharmacokinetic models incorpo-
rating those characteristics as covariates. Anesthesiology.
2003;98:299--305.
1. Schuttler J, Ihmsen H. Population pharmacokinetics of propofol:
a multicenter study. Anesthesiology. 2000;92:727--38.
2. Krejcie TC, Henthorn TK, Niemann CU, et al. Recirculatory phar-
macokinetics models of makers of blood, extracellular ﬂuid and
total body water administered concomitantly. J Pharmacol Exp
Ther. 1996;278:1050--7.
3. Upton RN, Grant C, Martinez AM, et al. Recirculatory model of
fentanyl disposition with the brain as the target organ. Br J
Anaesth. 2004;93:687--97.
4. Avram MJ, Krejcie TC. Using front-end kinetics to opti-
mize target-controlled drug infusion. Anesthesiology. 2003;99:
1078--86.
5. Henthorn TK, Krejcie TC, Avram MJ. Early drug distribution:
a generally neglected aspect of pharmacokinetics of particular
relevance to intravenously administered anesthesic agents. Clin
Pharmacol Ther. 2008;84:18--22.
6. Ludbrook GL, Visco E, Lam AM. Propofol: relation between
brain concentrations, electroencephalogram, middle cerebral
artery blood ﬂow velocity, and cerebral oxygen extraction dur-
ing induction of anesthesia. Anesthesiology. 2002;97:1363--70.
7. Schwilden H, Stoeckel H, Schuttler J. Closed-loop feedback con-
trol of propofol anaesthesia by quantitative EEG analysis in
humans. Br J Anaesth. 1989;62:290--6.
8. Billard V, Gambus PL, Chamoun N, et al. A comparison of spec-
tral edge, delta power, and bispectral index as EEG measures of
alfentanil, propofol, and midazolam drug effect. Clin Pharmacol
Ther. 1997;61:45--58.
9. White M, Schenkels MJ, Engbers FH, et al. Effect-site modelling
of propofol using auditory evoked potentials. Br J Anaesth.
1999;82:333--9.
0. Masui K, Kira M, Kasama T, et al. Early phase pharmacokinetics
but not pharmacodynamics are inﬂuenced by propofol infusuion
rate. Anesthesiology. 2009;111:805--17.
1. Doufas AG, Bakhshandeh M, Bjorksten AR, et al. Induction speed
is not a determinant of propofol pharmacodynamics. Anesthe-
siology. 2004;101:1112--21.
2. White M, Kenny GNC, Schraag S. Use of target controlled infu-
sion to derive age and gender covariates for propofol clearance.
Clin J Pharmacokinet. 2008;47:119--27.
